|
2024
|
Invention
|
Plk1 inhibitor in combination with anti-angiogenics for treating metastatic cancer.
Provided inc... |
|
|
Invention
|
Plk1 inhibitor in combination with anti-angiogenics for treating metastatic cancer. Provided incl... |
|
2023
|
Invention
|
Cancer treatment using mtdp inhibitors and plk1 inhibitors. Provided include methods, composition... |
|
|
Invention
|
Methods of monitoring mutations in treatment of colorectal cancer. Provided includes methods, com... |
|
|
Invention
|
Onvansertib and parp inhibitor combination. Disclosed herein include methods, compositions, and k... |
|
|
Invention
|
Cancer treatment using topoisomerase i inhibitors and plk1 inhibitors. Disclosed herein include m... |
|
|
Invention
|
Biomarkers for combination therapies. Disclosed herein include methods, compositions, and kits su... |
|
2022
|
Invention
|
Predictive biomarkers for onvansertib treatment.
Disclosed herein include methods, compositions,... |
|
|
Invention
|
Cancer treatment using lsd1 inhibitors and plk1 inhibitors.
Provided include methods, compositio... |
|
|
Invention
|
Cancer treatment using lsd1 inhibitors and plk1 inhibitors. Provided include methods, composition... |
|
|
Invention
|
Cancer treatment using fgfr inhibitors and plk1 inhibitors. Provided include methods, composition... |
|
|
Invention
|
Cancer treatment using parp inhibitors and plk1 inhibitors.
Provided include methods, compositio... |
|
|
Invention
|
Cancer treatment using parp inhibitors and plk1 inhibitors. Provided include methods, composition... |
|
2021
|
Invention
|
Selection and treatment of cancer with combination therapies.
Certain molecular characteristics ... |
|
|
Invention
|
Selection and treatment of cancer with combination therapies. Certain molecular characteristics o... |
|
|
Invention
|
Methods of monitoring kras mutations.
Provided includes methods, compositions and kits for impro... |
|
|
Invention
|
Methods of monitoring kras mutations. Provided includes methods, compositions and kits for improv... |
|
|
Invention
|
Treatment of leukemias and lymphomas with combinations of bcl-2 inhibitors and plk1 inhibitors.
... |
|
|
Invention
|
Treatment of leukemias and lymphomas with combinations of bcl-2 inhibitors and plk1 inhibitors. P... |
|
|
Invention
|
Circulating tumor dna as a biomarker for leukemia treatment.
Provided herein includes a method c... |
|
|
Invention
|
Circulating tumor dna as a biomarker for leukemia treatment. Provided herein includes a method co... |
|
2020
|
G/S
|
Pharmaceutical products development; Research and development in the pharmaceutical and biotechno... |
|
|
Invention
|
Plk1 inhibitors and psa levels in prostate cancer.
Provided is a method comprising recommending ... |
|
|
Invention
|
Plk1 inhibitors and psa levels in prostate cancer. Provided is a method comprising recommending t... |
|
|
Invention
|
Onvansertib for inhibiting non-adrenergic contraction of smooth muscle and prostate cell prolifer... |
|
2019
|
Invention
|
Nucleophosmin protein (npm) mutants, corresponding gene sequences and uses thereof.
The inventio... |
|
|
Invention
|
Plk1 target phosphorylation status and treatment of cancer with plk1 inhibitors.
Provided is a m... |
|
2017
|
Invention
|
Nucleophosmin protein (npm) mutants, corresponding gene sequences and uses thereof. The invention... |
|
2016
|
Invention
|
Synthesis and enrichment of nucleic acid sequences. The present disclosure relates to the enrichm... |
|
|
Invention
|
Early assessment of mechanism of action and efficacy of anti-cancer therapies using molecular mar... |
|
2015
|
Invention
|
Amplification and sequencing of transrenal nucleic acids. The present invention provides highly s... |
|
|
Invention
|
Compositions, methods and kits for isolating nucleic acids from body fluids using anion exchange ... |
|
2014
|
Invention
|
Method for detection of high risk human papillomavirus. The invention provides compositions and m... |
|
2009
|
Invention
|
Genetic marker for detection of human papillomavirus. The invention provides compositions and met... |
